Molecular target therapies in endometrial cancer: From the basic research to the clinic

References

• Bakkum-Gamez J N, Gonzalez-Bosquet J, Laack N N, Mariani A, Dowdy S C. Current issues in the management of endometrial cancer. Mayo Clin Proc 2008; 83: 97–112
   PubMed Web of Science ®Google Scholar
• Sherman M E, Kurman R J. Evolving concepts in endometrial carcinogenesis: importance of DNA repair and deregulated growth. Hum Pathol 1998; 29: 1035–1038
   PubMed Web of Science ®Google Scholar
• Matias-Guiu X, Catasus L, Bussaglia E, Lagarda H, Garcia A, Pons C, Muñoz J, Argüelles R, Machin P, Prat J. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 2001; 32: 569–577
   PubMed Web of Science ®Google Scholar
• Koul A, Willén R, Bendahl P O, Nilbert M, Borg A. Distinct sets of gene alterations in endometrial carcinoma implicate alternate modes of tumorigenesis. Cancer 2002; 94: 2369–2379
   PubMed Web of Science ®Google Scholar
• Lax S F. Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 2004; 444: 213–223
   PubMed Web of Science ®Google Scholar
• Mutch D G, Powell M A, Mallon M A, Goodfellow P J. RAS/RAF mutation and defective DNA mismatch repair in endometrial cancers. Am J Obstet Gynecol 2004; 190: 935–942
   PubMed Web of Science ®Google Scholar
• Pappa K I, Choleza M, Markaki S, Giannikaki E, Kyroudi A, Vlachos G, Voulgaris Z, Anagnou N P. Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status. Gynecol Oncol 2006; 100: 596–600
   PubMed Web of Science ®Google Scholar
• Abal M, Planaguma J, Gil-Moreno A, Monge M, Gonzalez M, Baro T, Garcia A, Castellvi J, Ramon Y, Cajal S, et al. Molecular pathology of endometrial carcinoma: transcriptional signature in endometrioid tumors. Histol Histopathol 2006; 21: 197–204
   PubMed Web of Science ®Google Scholar
• Maggino T, Romagnolo C, Zola P, Sartori E, Landoni F, Gadducci A. An analysis of approaches to the treatment of endometrial cancer in western Europe: a CTF study. Eur J Cancer 1995; 31A: 1993–1997
   PubMedGoogle Scholar
• Maggino T, Romagnolo C, Landoni F, Sartori E, Zola P. Gadducci A. An analysis of approaches to the management of endometrial cancer in North America: a CTF study. Gynecol Oncol 1998; 68: 274–279
   PubMedGoogle Scholar
• Kilgore L C, Partridge E E, Alvarez R D, Austin J M, Shingleton H M, Noojin F, 3rd, Conner W. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol 1995; 56: 29–33
   PubMed Web of Science ®Google Scholar
• Carey M S, O'Connell G J, Johanson C R, Goodyear M D, Murphy K J, Daya D M, Schepansky A, Peloquin A, Lumsden B J. Good outcome associated with a standardized treatment protocol using selective postoperative radiation in patients with clinical stage I adenocarcinoma of the endometrium. Gynecol Oncol 1995; 57: 138–144
   PubMedGoogle Scholar
• Eltabbakh G H, Piver M S, Hempling R E, Shin K H. Excellent long-term survival and absence of vaginal recurrences in 332 patients with low-risk stage I endometrial adenocarcinoma treated with hysterectomy and vaginal brachytherapy without formal staging lymph node sampling: report of a prospective trial. Int J Radiat Oncol Biol Phys 1997; 38: 373–380
   PubMed Web of Science ®Google Scholar
• Trimble E L, Kosary C, Park R C. Lymph node sampling and survival in endometrial cancer. Gynecol Oncol 1998; 71: 340–343
   Google Scholar
• Mariani A, Webb M J, Keeney G L, Haddock M G, Calori G, Podratz K C. Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary?. Am J Obstet Gynecol 2000; 182: 1506–1519
   PubMed Web of Science ®Google Scholar
• Cragun J M, Havrilesky L J, Calingaert B, Synan I, Secord A A, Soper J T, Clarke-Pearson D L, Berchuck A. Retrospective analysis of selective lymphadenectomy in apparent early-stage endometrial cancer. J Clin Oncol 2005; 23: 3668–3675
   PubMed Web of Science ®Google Scholar
• Mariani A, Dowdy S C, Cliby W A, Haddock M G, Keeney G L, Lesnick T G, Podratz K C. Efficacy of systematic lymphadenectomy and adjuvant radiotherapy in node-positive endometrial cancer patients. Gynecol Oncol 2006; 101: 200–208
   PubMed Web of Science ®Google Scholar
• Chan J K, Kapp D S. Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 2007; 8: 831–841
   PubMed Web of Science ®Google Scholar
• Fujimoto T, Nanjyo H, Nakamura A, Yokoyama Y, Takano T, Shoji T, Nakahara K, Yamada H, Mizunuma H, Yaegashi N, et al. Para-aortic lymphadenectomy may improve disease-related survival in patients with multipositive pelvic lymph node stage IIIc endometrial cancer. Gynecol Oncol 2007; 107: 253–259
   PubMed Web of Science ®Google Scholar
• Tozzi R, Malur S, Koehler C, Schneider A. Laparoscopy versus laparotomy in endometrial cancer: first analysis of survival of a randomized prospective study. J Minim Invasive Gynecol 2005; 12: 130–136
   PubMed Web of Science ®Google Scholar
• Schlaerth A C, Abu-Rustum N R. Role of minimally invasive surgery in gynecologic cancers. Oncologist 2006; 11: 895–901
   PubMed Web of Science ®Google Scholar
• Janda M, Gebski V, Forder P, Jackson D, Williams G, Obermair A. Total laparoscopic versus open surgery for stage 1 endometrial cancer: the LACE randomized controlled trial. Contemp Clin Trials 2006; 27: 353–363
   Google Scholar
• Cirisano F D, Jr, Robboy S J, Dodge R K, Bentley R C, Krigman H R, Synan I S, Soper J T, Clarke-Pearson D L. Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometriod carcinoma. Gynecol Oncol 1999; 74: 385–394
   PubMed Web of Science ®Google Scholar
• Bristow R E, Duska L R, Montz F J. The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma. Gynecol Oncol 2001; 81: 92–99
   PubMed Web of Science ®Google Scholar
• Chan J K, Loizzi V, Youssef M, Osann K, Rutgers J, Vasilev S A, Berman M L. Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium. Gynecol Oncol 2003; 90: 181–185
   PubMed Web of Science ®Google Scholar
• Slomovitz B M, Burke T W, Eifel P J, Ramondetta L M, Silva E G, Jhingran A, Oh J C, Atkinson E N, Broaddus R R, Gershenson D M, Lu K H. Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases. Gynecol Oncol 2003; 91: 463–469
   PubMed Web of Science ®Google Scholar
• Maggino T, Gadducci A. Uterine papillary serous carcinoma. Endometrial cancer. European practice in gynaecology and obstetrics series, P Bosze. Elsevier, Amsterdam 2003; 205–212
   Google Scholar
• Schwartz P E. The management of serous papillary uterine cancer. Curr Opin Oncol 2006; 18: 494–499
   PubMed Web of Science ®Google Scholar
• Havrilesky L J, Secord A A, Bae-Jump V, Ayeni T, Calingaert B, Clarke-Pearson D L, Berchuck A, Gehrig P A. Outcomes in surgical stage I uterine papillary serous carcinoma. Gynecol Oncol 2007; 105: 677–682
   PubMedGoogle Scholar
• Johnson N, Cornes P. Survival and recurrent disease after postoperative radiotherapy for early endometrial cancer: systematic review and meta-analysis. BJOG 2007; 114: 1313–1320
   PubMed Web of Science ®Google Scholar
• Jolly S, Vargas C, Kumar T, Weiner S, Brabbins D, Chen P, Floyd W, Martinez A A. Vaginal brachytherapy alone: an alternative to adjuvant whole pelvis radiation for early stage endometrial cancer. Gynecol Oncol 2005; 97: 887–892
   PubMed Web of Science ®Google Scholar
• Rankins N C, Secord A A, Jewell E, Havrilesky L J, Soper J T, Myers E. Cost-effectiveness of adjuvant radiotherapy in intermediate risk endometrial cancer. Gynecol Oncol 2007; 106: 388–393
   Google Scholar
• Creutzberg C L. PORTEC2: Postoperative Radiation Therapy for Endometrial Carcinoma – a multicenter randomised phase III trial comparing external beam radiation and vaginal brachytherapy [Internet]. Leiden University Medical Centre, LeidenThe Netherlands 2003, Available from: http://www.clinicalresearch.nl/portec2/PORTEC-2
   Google Scholar
• Corn B W, Lanciano R M, Greven K M, Schultz D J, Reisinger S A, Stafford P M, Hanks G E. Endometrial cancer with para-aortic adenopathy: patterns of failure and opportunities for cure. Int J Radiat Oncol Biol Phys 1992; 24: 223–227
   PubMed Web of Science ®Google Scholar
• Rose P G, Cha S D, Tak W K, Fitzgerald T, Reale F, Hunter R E. Radiation therapy for surgically proven para-aortic node metastasis in endometrial carcinoma. Int J Radiat Oncol Biol Phys 1992; 24: 229–233
   PubMed Web of Science ®Google Scholar
• De Palo G, Mangioni C, Periti P, Del Vecchio M, Marubini E. Treatment of FIGO (1971) stage I endometrial carcinoma with intensive surgery, radiotherapy and hormonotherapy according to pathological prognostic groups. Long-term results of a randomised multicentre study. Eur J Cancer 1993; 29A: 1133–1140
   PubMedGoogle Scholar
• Rotman M, Aziz H, Boronow R. Insights in para-aortic radiation therapy for endometrial carcinoma. Int J Radiat Oncol Biol Phys 1993; 26: 711–712
   Google Scholar
• Mundt A J, McBride R, Rotmensch J, Waggoner S E, Yamada S D, Connell P P. Significant pelvic recurrence in high risk pathologic stage I–IV endometrial carcinoma patients after adjuvant chemotherapy alone: implications for adjuvant radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50: 1145–1153
   PubMed Web of Science ®Google Scholar
• Maggi R, Lissoni A, Spina F, Melpignano M, Zola P, Favalli G, Colombo A, Fossati R. Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomized trial. Br J Cancer 2006; 95: 266–271
   PubMed Web of Science ®Google Scholar
• Randall M E, Filiaci V L, Muss H, Spirtos N M, Mannel R S, Fowler J, Thigpen J T, Benda J A, Gynecologic Oncology Group Study. Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2006; 24: 36–44
   PubMed Web of Science ®Google Scholar
• Kodama J, Seki N, Hiramatsu Y. Chemotherapy for high-risk early-stage endometrial cancer. Curr Opin Obstet Gynecol 2007; 19: 42–47
   Google Scholar
• Hiura M, Nogawa T, Matsumoto T, Yokoyama T, Shiroyama Y, Wroblewski J, Hirata E. Long-term survival in patients with para-aortic lymph node metastasis with systematic retroperitoneal lymphadenectomy followed by adjuvant chemotherapy in endometrial carcinoma 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(Suppl)16011, (abstract)
   Google Scholar
• Susumu N, Sagae S, Udagawa Y, Niwa K, Kuramoto H, Satoh S, Kudo R, Japanese Gynecologic Oncology Group. Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108: 226–233
   PubMed Web of Science ®Google Scholar
• Onda T, Yoshikawa H, Mizutani K, Mishima M, Yokota H, Nagano H, Ozaki Y, Murakami A, Ueda K, Taketani Y. Treatment of node-positive endometrial cancer with complete node dissection, chemotherapy and radiation therapy. Br J Cancer 1997; 75: 1836–1841
   PubMed Web of Science ®Google Scholar
• Greven K, Winter K, Underhill K, Fontenesci J, Cooper J, Burke T. Final analysis of RTOG 9708: adjuvant postoperative irradiation combined with cisplatin/paclitaxel chemotherapy following surgery for patients with high-risk endometrial cancer. Gynecol Oncol 2006; 103: 155–159
   PubMed Web of Science ®Google Scholar
• Mangili G, De Marzi P, Beatrice S, Rabaiotti E, Viganò R, Frigerio L, Gentile C, Fazio F. Paclitaxel and concomitant radiotherapy in high-risk endometrial cancer patients: preliminary findings. BMC Cancer 2006; 6: 198
   PubMedGoogle Scholar
• Lupe K, Kwon J, D'Souza D, Gawlik C, Stitt L, Whiston F, Nascu P, Wong E, Carey M S. Adjuvant paclitaxel and carboplatin chemotherapy with involved field radiation in advanced endometrial cancer: a sequential approach. Int J Radiat Oncol Biol Phys 2007; 67: 110–116
   PubMed Web of Science ®Google Scholar
• Bancher-Todesca D, Neunteufel W, Williams K E, Prainsack D, Breitenecker G, Friedlander M L, Hacker N F. Influence of postoperative treatment on survival in patients with uterine papillary serous carcinoma. Gynecol Oncol 1998; 71: 344–347
   PubMedGoogle Scholar
• Santin A D, Bellone S, O'Brien T J, Pecorelli S, Cannon M J, Roman J J. Current treatment options for endometrial cancer. Expert Rev Anticancer Ther 2004; 4: 679–689
   PubMedGoogle Scholar
• Kelly M G, O'Malley D M, Hui P, McAlpine J, Yu H, Rutherford T J, Azodi M, Schwartz P E. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy. Gynecol Oncol 2005; 98: 353–359
   PubMed Web of Science ®Google Scholar
• Duska L R, Berkowitz R, Matulonis U, Muto M, Goodman A, McIntyre J F, Klein A, Atkinson T, Seiden M V, Campos S. A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with “high-risk” endometrial cancer. Gynecol Oncol 2005; 96: 198–203
   Google Scholar
• Huh W K. What is the correct management of stage IUPSC?. Int J Gynecol Cancer 2005; 15: 405–406
   Google Scholar
• Dietrich C S, 3rd, Modesitt S C, DePriest P D, Ueland F R, Wilder J, Reedy M B, Pavlik E J, Kryscio R, Cibull M, Giesler J, et al. The efficacy of adjuvant platinum-based chemotherapy in stage I uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2005; 99: 557–563
   PubMedGoogle Scholar
• Hamilton C A, Liou W S, Osann K, Berman M L, Husain A, Teng N N, Kapp D S, Chan J K. Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma. Int J Radiat Oncol Biol Phys 2005; 63: 839–844
   PubMed Web of Science ®Google Scholar
• Low J S, Wong E H, Tan H S, Yap S P, Chua E J, Sethi V K, Soh L T, Low J, Tay E H, Chew S H. Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma. Gynecol Oncol 2005; 97: 171–177
   PubMed Web of Science ®Google Scholar
• Steed H, Manchul L, Rosen B, Fyles A, Lockwood G, Laframboise S, Murphy J, Milosevic M, Chapman W, Oza A M. Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy. Int J Gynecol Cancer 2006; 16: 278–285
   PubMed Web of Science ®Google Scholar
• Thomas M B, Mariani A, Cliby W A, Keeney G A, Podratz K C, Dowdy S C. Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma. Gynecol Oncol 2007; 107: 186–189
   PubMedGoogle Scholar
• Viswanathan A, Horick N, Tanaka C, Campos S, Matulonis U, Berkowitz R. Chemotherapy and radiation therapy in UPSC. J Clin Oncoll, 2007 2007; 25(18S)5535, ASCO Annual Meeting Proceedings Part I
   Google Scholar
• Fields A L, Einstein M H, Novetsky A P, Gebb J, Goldberg G L. Pilot phase II trial of radiation ‘sandwiched’ between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC). Gynecol Oncol 2008; 108: 201–206
   PubMed Web of Science ®Google Scholar
• Thigpen J T, Brady M F, Alvarez R D, Adelson M D, Homesley H D, Manetta A, Soper J T, Given F T. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose–response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736–1744
   PubMed Web of Science ®Google Scholar
• Decruze S B, Green J A. Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17: 964–978
   PubMed Web of Science ®Google Scholar
• Lai C, Huang H. The role of hormones for the treatment of endometrial hyperplasia and endometrial cancer. Curr Opin Obstet Gynecol 2006; 18: 29–34
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Genazzani A R. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 2006; 58: 242–256
   PubMed Web of Science ®Google Scholar
• Pectasides D, Pectasides E, Economopoulos T. Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 2007; 33: 177–190
   PubMed Web of Science ®Google Scholar
• Garrett A, Quinn M A. Hormonal therapies and gynaecological cancers. Best Pract Res Clin Obstet Gynaecol Sep 18, 2007, [Epub ahead of print]
   Google Scholar
• Aapro M S, van Wijk F H, Bolis G, Chevallier B, van der Burg M E, Poveda A, de Oliveira C F, Tumolo S, Scotto di Palumbo V, Piccart M, et al. European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer Group. Ann Oncol 2003; 14: 441–448
   PubMed Web of Science ®Google Scholar
• Thigpen J T, Brady M F, Homesley H D, Malfetano J, DuBeshter B, Burger R A, Liao S. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3902–3908
   PubMed Web of Science ®Google Scholar
• van Wijk F H, Lhommé C, Bolis G, Scotto di Palumbo V, Tumolo S, Nooij M, de Oliveira C F, Vermorken J B, European Organization for Research and Treatment of Cancer. Gynaecological Cancer Group. Phase II study of carboplatin in patients with advanced or recurrent endometrial carcinoma. A trial of the EORTC Gynaecological Cancer Group. Eur J Cancer 2003; 39: 78–85
   PubMed Web of Science ®Google Scholar
• Fleming G F, Brunetto V L, Cella D, Look K Y, Reid G C, Munkarah A R, Kline R, Burger R A, Goodman A, Burks R T. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 2159–2166
   PubMed Web of Science ®Google Scholar
• Akram T, Maseelall P, Fanning J. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer. Am J Obstet Gynecol 2005; 192: 1365–1367
   PubMed Web of Science ®Google Scholar
• McMeekin D S, Filiaci V L, Thigpen J T, Gallion H H, Fleming G F, Rodgers W H, Gynecologic Oncology Group study. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 2007; 106: 16–22
   PubMed Web of Science ®Google Scholar
• Secord A A, Havrilesky L J, Carney M E, Soper J T, Clarke-Pearson D L, Rodriguez G C, Berchuck A. Weekly low-dose paclitaxel and carboplatin in the treatment of advanced or recurrent cervical and endometrial cancer. Int J Clin Oncol 2007; 12: 31–36
   PubMed Web of Science ®Google Scholar
• Pignata S, Scambia G, Pisano C, Breda E, Di Maio M, Greggi S, Ferrandina G, Lorusso D, Zagonel V, Febbraro A, et al. Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies Group. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: the END-1 study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies) group. Br J Cancer 2007; 96: 1639–1643
   PubMed Web of Science ®Google Scholar
• Mountzios G, Bamias A, Voulgaris Z, Rodolakis A, Vlahos G, Gourgoulis G, Papaiakovou E E, Giannopoulos A. Prognostic factors in patients treated with taxane-based chemotherapy for recurrent or metastatic endometrial cancer: proposal for a new prognostic model. Gynecol Oncol 2008; 108: 130–135
   Google Scholar
• Kew F M, Roberts A P, Cruickshank D J. The role of routine follow-up after gynecological malignancy. Int J Gynecol Cancer 2005; 15: 413–419
   PubMed Web of Science ®Google Scholar
• Albitar L, Laidler L L, Abdallah R, Leslie K K. Regulation of signaling phosphoproteins by epidermal growth factor and Iressa (ZD1839) in human endometrial cancer cells that model type I and II tumors. Mol Cancer Ther 2005; 4: 1891–1899
   Google Scholar
• De Luca A, Carotenuto A, Rachiglio A, Gallo M, Maiello M R, Aldinucci D, Pinto A, Normanno N. The role of the EGFR signaling in tumor microenvironment. J Cell Physiol 2008; 214: 559–567
   PubMed Web of Science ®Google Scholar
• Kitao K, Yoshida S, Kennedy S, Takemura N, Sugimoto M, Deguchi M, Ohara N, Maruo T. Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population. Reprod Sci 2007; 14: 349–357
   Google Scholar
• Khalifa M A, Mannel R S, Haraway S D, Walker J, Min K W. Expression of EGFR, HER2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas. Gynecol Oncol 1994; 53: 84–92
   PubMed Web of Science ®Google Scholar
• Reinartz J J, George E, Lindgren B R, Niehans G A. Expression of p53, transforming growth factor α, epidermal growth factor receptor, and c-erbB-2 in endometrial carcinoma and correlation with survival and known predictors of survival. Hum Pathol 1994; 25: 1075–1083
   PubMed Web of Science ®Google Scholar
• Scambia G, Benedetti Panici P, Ferrandina G, Battaglia F, Distefano M, D'Andrea G, De Vincenzo R, Maneschi F, Ranelletti F O, Mancuso S. Significance of epidermal growth factor receptor expression in primary human endometrial cancer. Int J Cancer 1994; 56: 26–30
   PubMed Web of Science ®Google Scholar
• Niikura H, Sasano H, Matsunaga G, Watanabe K, Ito K, Sato S, Yajima A. Prognostic value of epidermal growth factor receptor expression in endometrioid endometrial carcinoma. Hum Pathol 1995; 26: 892–896
   PubMed Web of Science ®Google Scholar
• Yokoyama Y, Takahashi Y, Hashimoto M, Morishita S, Tamaya T. Immunohistochemical study of estradiol, epidermal growth factor, transforming growth factor α and epidermal growth factor receptor in endometrial neoplasia. Jpn J Clin Oncol 1996; 26: 411–416
   Google Scholar
• Nagai N, Oshita T, Fujii T, Kioka H, Katsube Y, Ohama K. Prospective analysis of DNA ploidy, proliferative index and epidermal growth factor receptor as prognostic factors for pretreated uterine cancer. Oncol Rep 2000; 7: 551–559
   Google Scholar
• Brys M, Semczuk A, Rechberger T, Krajewska W M. Expression of erbB-1 and erbB-2 genes in normal and pathological human endometrium. Oncol Rep 2007; 18: 261–265
   Google Scholar
• Niikura H, Sasano H, Kaga K, Sato S, Yajima A. Expression of epidermal growth factor family proteins and epidermal growth factor receptor in human endometrium. Hum Pathol 1996; 27: 282–289
   PubMed Web of Science ®Google Scholar
• Dai D, Litman E S, Schonteich E, Leslie K K. Progesterone regulation of activating protein-1 transcriptional activity: a possible mechanism of progesterone inhibition of endometrial cancer cell growth. J Steroid Biochem Mol Biol 2003; 87: 123–131
   PubMedGoogle Scholar
• Davies S, Dai D, Wolf D M, Leslie K K. Immunomodulatory and transcriptional effects of progesterone through progesterone A and B receptors in Hec50co poorly differentiated endometrial cancer cells. J Soc Gynecol Investig 2004; 11: 494–499
   Google Scholar
• Davies S, Dai D, Feldman I, Pickett G, Leslie K K. Identification of a novel mechanism of NF-κB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. Gynecol Oncol 2004; 94: 463–470
   Google Scholar
• Dai D, Albitar L, Nguyen T, Laidler L L, Singh M, Leslie K K. A therapeutic model for advanced endometrial cancer: systemic progestin in combination with local adenoviral-mediated progesterone receptor expression. Mol Cancer Ther 2005; 4: 169–175
   Google Scholar
• Davies S, Dai D, Pickett G, Leslie K K. Gene regulation profiles by progesterone and dexamethasone in human endometrial cancer Ishikawa H cells. Gynecol Oncol 2006; 101: 62–70
   Google Scholar
• Albitar L, Carter M B, Davies S, Leslie K K. Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer. Gynecol Oncol 2007; 106: 94–104
   PubMed Web of Science ®Google Scholar
• Honda R, Tanaka H, Yasuda H. Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. FEBS Lett 1997; 420: 25–27
   PubMed Web of Science ®Google Scholar
• Tovar C, Rosinski J, Filipovic Z, Higgins B, Kolinsky K, Hilton H, Zhao X, Vu B T, Qing W, Packman K, et al. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy. Proc Natl Acad Sci USA 2006; 103: 1888–1893
   PubMed Web of Science ®Google Scholar
• Zhao S, Chen X, Lu X, Yu Y, Feng Y. Epidermal growth factor receptor signaling enhanced by long-term medroxyprogesterone acetate treatment in endometrial carcinoma. Gynecol Oncol 2007; 105: 45–54
   Google Scholar
• Leslie K K, Laidler L, Albitar L, Davies S, Holmes A, Nguyen T, Bolnick J, Dai D. Tyrosine kinase inhibitors in endometrial cancer. Int J Gynecol Cancer 2005; 15: 409–411
   Google Scholar
• Jasa K V, Fyles A, Elit L, Hoskins P J, Biagi J, Dubuc-Lissoir J, Matthews S, Dancey J, Eisenhauer E, Oza A M. Phase II study of erlotinib (OSI 774) in women with recurrent or metastatic endometrial cancer: NCIC CTG IND-148. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22(Suppl)5019
   Google Scholar
• Moy B, Goss P E. Lapatinib-associated toxicity and practical management recommendations. Oncologist 2007; 12: 756–765
   PubMed Web of Science ®Google Scholar
• Geyer C E, Forster J, Lindquist D, Chan S, Romieu C G, Pienkowski T, Jagiello-Gruszfeld A, Crown J, Chan A, Kaufman B, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. Oncologist 2007; 12: 756–765
   Google Scholar
• Prat J, Oliva E, Lerma E, Vaquero M, Matías-Guiu X. Uterine papillary serous adenocarcinoma. A 10-case study of p53 and c-erbB-2 expression and DNA content. Cancer 1994; 74: 1778–1783
   PubMed Web of Science ®Google Scholar
• Santin A D, Bellone S, Gokden M, Palmieri M, Dunn D, Agha J, Roman J J, Hutchins L, Pecorelli S, O'Brien T, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res 2002; 8: 1271–1279
   PubMed Web of Science ®Google Scholar
• Villella J A, Cohen S, Smith D H, Hibshoosh H, Hershman D. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer 2006; 16: 1897–1902
   PubMed Web of Science ®Google Scholar
• Santin A D, Zhan F, Bellone S, Palmieri M, Cane S, Gokden M, Roman J J, O'Brien T J, Tian E, Cannon M J, et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumors by gene expression profiling. Br J Cancer 2004; 90: 1814–1824
   PubMedGoogle Scholar
• Slomovitz B M, Broaddus R R, Burke T W, Sneige N, Soliman P T, Wu W, Sun C C, Munsell M F, Gershenson D M, Lu K H. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol 2004; 22: 3126–3132
   PubMed Web of Science ®Google Scholar
• Santin A D, Zhan F, Cane’ S, Bellone S, Palmieri M, Thomas M, Burnett A, Roman J J, Cannon M J, Shaughnessy J, Jr, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer 2005; 92: 1561–1573
   PubMed Web of Science ®Google Scholar
• Santin A D, Bellone S, Siegel E R, Palmieri M, Thomas M, Cannon M J, Kay H H, Roman J J, Burnett A, Pecorelli S. Racial differences in the overexpression of epidermal growth factor type II receptor (HER2/neu): a major prognostic indicator in uterine serous papillary cancer. Am J Obstet Gynecol 2005; 192: 813–818
   PubMed Web of Science ®Google Scholar
• Lukes A S, Kohler M F, Pieper C F, Kerns B J, Bentley R, Rodriguez G C, Soper J T, Clarke-Pearson D L, Bast R C, Jr. Berchuck A. Multivariable analysis of DNA ploidy, p53, and HER-2/neu as prognostic factors in endometrial cancer. Cancer 1994; 73: 2380–2385
   Google Scholar
• Capdeville R, Silberman S, Dimitrijevic S. Imatinib: the first 3 years. Eur J Cancer 2002; 38(Suppl 5)S77–S82
   Google Scholar
• Slomovitz B M, Broaddus R R, Schmandt R, Wu W, Oh J C, Ramondetta L M, Burke T W, Gershenson D M, Lu K H. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma. Gynecol Oncol 2004; 95: 32–36
   PubMed Web of Science ®Google Scholar
• Slomovitz B M, Ramondetta L M, Johnston T, Lu K H, Broaddus R R, Muller P, Iyer R B, Burke T W, Gershenson D M, Wolf J. A phase I study of imatinib mesylate and paclitaxel in patients with advanced (stage IIIC/IV) or recurrent uterine papillary serous carcinoma (UPSC) 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(Suppl)16025
   Google Scholar
• Chang F, Lee J T, Navolanic P M, Steelman L S, Shelton J G, Blalock W L, Franklin R A, McCubrey J A. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 2003; 1: 590–603
   Google Scholar
• McCubrey J A, Steelman L S, Abrams S L, Lee J T, Chang F, Bertrand F E, Navolanic P M, Terrian D M, Franklin R A, D'Assoro A B, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249–279
   PubMedGoogle Scholar
• Jastrzebski K, Hannan K M, Tchoubrieva E B, Hannan R D, Pearson R B. Coordinate regulation of ribosome biogenesis and function by the ribosomal protein S6 kinase, a key mediator of mTOR function. Growth Factors 2007; 25: 209–226
   PubMed Web of Science ®Google Scholar
• Hashemolhosseini S, Nagamine Y, Morley S J, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998; 273: 14424–14429
   PubMed Web of Science ®Google Scholar
• De Benedetti A, Graff J R. eIF-4E expression and its role in malignancies and metastases. Oncogene 2004; 23: 3189–3199
   PubMed Web of Science ®Google Scholar
• Sansal I, Sellers W R. The biology and clinical relevance of the PTEN tumor suppressor pathway. J Clin Oncol 2004; 22: 2954–2963
   PubMed Web of Science ®Google Scholar
• Tashiro H, Blazes M S, Wu R, Cho K R, Bose S, Wang S I, Li J, Parsons R, Ellenson L H. Mutations in PTEN are frequent in endometrial carcinoma but rare in other common gynecological malignancies. Cancer Res 1997; 57: 3935–3940
   PubMed Web of Science ®Google Scholar
• Risinger J I, Hayes K, Maxwell G L, Carney M E, Dodge R K, Barrett J C, Berchuck A. PTEN mutation in endometrial cancers is associated with favorable clinical and pathologic characteristics. Clin Cancer Res 1998; 4: 3005–3010
   PubMed Web of Science ®Google Scholar
• Lin W M, Forgacs E, Warshal D P, Yeh I T, Martin J S, Ashfaq R, Muller C Y. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas. Clin Cancer Res 1998; 4: 2577–2583
   PubMed Web of Science ®Google Scholar
• Bussaglia E, del Rio E, Matias-Guiu X, Prat J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum Pathol 2000; 31: 312–317
   PubMed Web of Science ®Google Scholar
• Mutter G L, Lin M C, Fitzgerald J T, Kum J B, Baak J P, Lees J A, Weng L P, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000; 92: 924–930
   PubMed Web of Science ®Google Scholar
• An H J, Lee Y H, Cho N H, Shim J Y, Kim J Y, Lee C, Kim S J. Alteration of PTEN expression in endometrial carcinoma is associated with down-regulation of cyclin-dependent kinase inhibitor, p27. Histopathology 2002; 41: 437–445
   PubMed Web of Science ®Google Scholar
• Terakawa N, Kanamori Y, Yoshida S. Loss of PTEN expression followed by Akt phosphorylation is a poor prognostic factor for patients with endometrial cancer. Endocr Relat Cancer 2003; 10: 203–208
   PubMed Web of Science ®Google Scholar
• Slomovitz B M, Wu W, Broaddus R R, Soliman P T, Wolf J, Sun C C, Bodurka D C, Gershenson D M, Lu K H. mTOR inhibition is a rational target for the treatment of endometrial cancer. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2004; 22(Suppl)5076
   Google Scholar
• Dutcher J P. Mammalian target of rapamycin inhibition. Clin Cancer Res 2004; 10: 6382S–6387S
   PubMed Web of Science ®Google Scholar
• Dudkin L, Dilling M B, Cheshire P J, Harwood F C, Hollingshead M, Arbuck S G, Travis R, Sausville E A, Houghton P J. Biochemical correlates of mTOR inhibition by the rapamycin ester CCI-779 and tumor growth inhibition. Clin Cancer Res 2001; 7: 1758–1764
   PubMed Web of Science ®Google Scholar
• Peralba J M, DeGraffenried L, Friedrichs W, Fulcher L, Grünwald V, Weiss G, Hidalgo M. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003; 9: 2887–2892
   PubMed Web of Science ®Google Scholar
• Oza A M, Elit L, Biagi J, Chapman W, Tsao M, Hedley D, Hansen C, Dancey J, Eisenhauer E. Molecular correlates associated with a phase II study of tensirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer – NCIC IND 160. 2006 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2006; 24(Suppl)3003
   Google Scholar
• Mita M M, Mita A, Rowinski E K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003; 4: 126–137
   PubMedGoogle Scholar
• Boulay A, Zumstein-Mecker S, Stephan C, Beuvink I, Zilbermann F, Haller R, Tobler S, Heusser C, O'Reilly T, Stolz B, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252–261
   PubMed Web of Science ®Google Scholar
• Wolf J, Slomovitz B M. Novel biologic therapies for the treatment of endometrial cancer. Int J Gynecol Cancer 2005; 15: 411
   Google Scholar
• Dancey J E. Inhibitors of the mammalian target of rapamycin. Expert Opin Investig Drugs 2005; 14: 313–328
   PubMed Web of Science ®Google Scholar
• Colombo N, McMeekin S, Schwartz P, Kostka J, Sessa C, Gehrig P, Holloway R, Braly P, Matei D, Einstein M. A phase II trial of the mTOR inhibitor AP23573 as a single agent in advanced endometrial cancer. 2007 ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(Suppl)5516
   Google Scholar
• Santin A D, Bellone S, Marizzoni M, Palmieri M, Siegel E R, McKenney J K, Hennings L, Comper F, Bandiera E, Pecorelli S. Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). Cancer 2007; 109: 1312–1322
   PubMedGoogle Scholar
• Michl P, Buchholz M, Rolke M, Kunsch S, Löhr M, McClane B, Tsukita S, Leder G, Adler G, Gress T M. Claudin-4: a new target for pancreatic cancer treatment using Clostridium perfringens enterotoxin. Gastroenterology 2001; 121: 678–684
   Google Scholar
• Santin A D, Bellone S, Siegel E R, McKenney J K, Thomas M, Roman J J, Burnett A, Tognon G, Bandiera E, Pecorelli S. Overexpression of Clostridium perfringens enterotoxin receptors claudin-3 and claudin-4 in uterine carcinosarcomas. Clin Cancer Res 2007; 13: 3339–3346
   PubMed Web of Science ®Google Scholar
• Hirai M, Nakagawara A, Oosaki T, Hayashi Y, Hirono M, Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol Oncol 2001; 80: 181–188
   PubMed Web of Science ®Google Scholar
• Holland C M, Day K, Evans A, Smith S K. Expression of the VEGF and angiopoietin genes in endometrial atypical hyperplasia and endometrial cancer. Br J Cancer 2003; 89: 891–898
   PubMed Web of Science ®Google Scholar
• Kamat A A, Merritt W M, Coffey D, Lin Y G, Patel P R, Broaddus R, Nugent E, Han L Y, Landen C N, Jr, Spannuth W A, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res 2007; 13: 7487–7495
   PubMed Web of Science ®Google Scholar
• Wright J D, Powell M A, Rader J S, Mutch D G, Gibb R K. Bevacizumab therapy in patients with recurrent uterine neoplasms. Anticancer Res 2007; 27: 3525–3528
   PubMed Web of Science ®Google Scholar
• Dinh P, de Azambuja E, Piccart-Gebhart M J. Trastuzumab for early breast cancer: current status and future directions. Clin Adv Hematol Oncol 2007; 5: 707–717
   Google Scholar
• Palandri F, Iacobucci I, Martinelli G, Amabile M, Poerio A, Testoni N, Soverini S, Castagnetti F, De Vivo A, Breccia M, et al. GIMEMA Working Party on CML. Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party of CML. J Clin Oncol 2008; 26: 106–111
   PubMed Web of Science ®Google Scholar
• Trent J C, Lazar A J, Zhang W. Molecular approaches to resolve diagnostic dilemmas: the case of gastrointestinal stromal tumor and leiomyosarcoma. Future Oncol 2007; 3: 629–637
   Google Scholar
• Benson A B, 3rd. New approaches to assessing and treating early-stage colon and rectal cancers: cooperative group strategies for assessing optimal approaches in early-stage disease. Clin Cancer Res 2007; 13: 6913s–6920s
   PubMedGoogle Scholar
• Klein B, Gottfried M. Targeted agents to improve treatment results in colon cancer: bevacizumab and cetuximab. J BUON 2007; 12(Suppl 1)S127–S136
   Google Scholar
• Samlowski W E, Vogelzang N J. Emerging drugs for the treatment of metastatic renal cancer. Expert Opin Emerg Drugs 2007; 12: 605–618
   PubMed Web of Science ®Google Scholar
• Cerezo L, Cárdenes H, Michael H. Molecular alterations in the pathogenesis of endometrial adenocarcinoma. Therapeutic implications. Clin Transl Oncol 2006; 8: 231–241
   PubMedGoogle Scholar